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54 Abstract
55 Introduction – Healthcare delivery is being transformed by COVID-19 to reduce 
56 transmission risk but continued delivery of routine clinical tests is essential. Stress 
57 echocardiography is one of the most widely used cardiac tests in the NHS. We assessed the 
58 impact of the first (W1) and second (W2) waves of the pandemic on ability to deliver stress 
59 echocardiography.
60 Methods – Clinical echocardiography teams in 31 NHS hospitals participating in the 
61 EVAREST study were asked in July and November 2020 to complete a survey on the 
62 structure and delivery of stress echocardiography as well as impact on patients and staff. 
63 Results were compared to stress echocardiography activity in the same centre during January 
64 2020.
65 Results – 24 and 19 NHS hospitals completed the survey in July and November, 
66 respectively. A 55% reduction in the number of studies performed was reported in W1, 
67 recovering to exceed pre-COVID rates in W2. The major change was in mode of stress 
68 delivery. 70% of sites stopped their exercise stress service in W1, compared to 19% in W2. In 
69 those still using exercise during W1, 50% were wearing FFP3/N95 masks, falling to 38% in 
70 W2. There was also significant variability in patient screening practices with 7 different pre-
71 screening questionnaires used in W1 and 6 in W2. 
72 Conclusion – Stress echocardiography delivery restarted effectively after COVID-19 with 
73 adaptations to reduce transmission that means activity has been able to continue, and exceed, 
74 pre-COVID-19 levels during the second wave. Further standardization of protocols for 
75 patient screening and PPE may help further improve consistency of practice within the UK. 
76
77 Keywords: Stress Echocardiography, COVID-19, Coronary Artery Disease, Ischaemic 
78 Heart Disease, Survey, National Health Services.
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81 The Coronavirus (COVID-19) pandemic is placing unprecedented strain on healthcare 
82 services across the world1, with the UK’s National Health Service (NHS) experiencing its 
83 greatest challenge in 70 years of existence2. The disease has spread rapidly across the UK3 
84 with now over 60,000 COVID-19 related deaths recorded in the country3. NHS activity 
85 restarted4 following the first wave of COVID-19 infections, but with new regulations to 
86 minimise patient contact with healthcare professionals and reduce risk of transmission via 
87 aerosol generating procedures5,6,7,8. Stress echocardiography is one of the most widely used 
88 tests to assess cardiac function and determine whether a patient has evidence of coronary 
89 ischaemia9,10,11. Therefore, continued delivery of stress echocardiography is essential to 
90 deliver effective healthcare within the NHS. We studied whether COVID-19 and associated 
91 healthcare regulations had impacted ability to deliver stress echocardiography in the NHS. 
92
93 Methods
94 The ‘Impact of COVID-19 on UK Stress Echocardiography Services’ survey was sent to the 
95 research teams from the 31 NHS hospitals participating in the EVAREST study 
96 (ClinicalTrials.gov ID: NCT03674255) in both July and November 2020 . The EVAREST 
97 study is a UK-wide prospective stress echocardiography study that aims to evaluate real 
98 world performance, accuracy and cost of stress echocardiography and has been running since 
99 2011. The existing network of UK hospitals, set up as a part of the EVAREST study, 
100 provided the infrastructure to distribute the survey and collect results from hospitals across 
101 the UK. Survey results could be compared to historical data from the same centres based on 
102 the data collected withn the EVAREST study, as well as comparing the results between the 
103 two waves of COVID-19. The survey was developed as a consensus document in 
104 collaboration with the British Society of Echocardiography (BSE) and contained questions 
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105 focussed around the impact of COVID-19 on stress echocardiography practice, patients and 
106 NHS staff (Appendix 1). The survey was deployed electronically to 31 NHS sites via Google 
107 Forms (Google LLC., Mountain View, California, United States). Responses from the sites 
108 were collated after 10 days. 
109
110 Statistical Analysis
111 Hospital characteristics and reported data from the NHS sites were reported using standard 
112 approaches. To calculate the significance level of the difference in estimated numbers of 
113 stress echocardiography studies performed before and during the two waves of the pandemic 
114 (Figure 3), a paired two-tailed distribution t-test was used with a significance level of p<0.05 




119 A total of 24 NHS hospitals (77%) responded to the survey in July, immediately after the 
120 peak of the first wave (W1) and 19 hospitals (61%) in November in the middle of the second 
121 wave (W2). 17 hospitals responded to both surveys. Data on the geographical spread, index of 
122 multiple deprivation, the number of hospital beds, the number of cardiology attendances and 
123 self-reported numbers of stress echocardiograms performed per annum at each site are 
124 presented in Figure 1. 
125
126 Stress Echo Practice
127 Figure 2A illustrates that stress echocardiography was being performed at 21 sites (87.5%) 
128 with 3 having stopped their service entirely in W1. During W2, stress echocardiography was 
129 being performed at all 19 sites (100%), with 8 sites (42%) reporting their stress 
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130 echocardiography service was now unaffected by COVID-19. The number of sessions being 
131 performed at sites was reduced during W1 (range 1 to 11 sessions per week) compared to pre 
132 COVID-19 (range 1 to 20), recovering back to a range of 1-20 sessions per week reported by 
133 sites during W2. Figure 2D shows a reduction in the number of patients seen in each stress 
134 echocardiography session, from 4 ± 0 pre-COVID to 2.7 ± 0.4 during W1 and 2.9 ± 0.3 
135 during W2.
136
137 Using data from sites that indicated their numbers of stress echo sessions during both W1 and 
138 W2, Figure 3 shows an overall 55% reduction in the estimated number of studies performed 
139 per month compared to pre-COVID-19 rates (78 ± 65 per month pre-COVID-19 vs 35 ± 32 
140 per month during W1, p<0.05). The estimated number of studies performed during W2 
141 increased to more than reported during W1 (71 ± 79 per month during W2 vs 35 ± 32 per 
142 month during W1, p<0.05). The estimated number of studies performed during W2 was not 
143 significantly different to pre-COVID-19 rates (71 ± 79 per month during W2 vs 78 ± 65 per 
144 month pre-COVID-19, p>0.05).
145
146 Figure 3B shows that in higher volume sites, the estimated number of studies per week fell 
147 from 116 studies per week pre-COVID to 58 per week in W1 (50% fall, p <0.05). This 
148 recovered to 125 per week in W2. (108% of pre-COVID levels). In smaller sites (Figure 3B), 
149 studies per week fell from 40 studies per week pre-COVID to 17 per week in W1 (42% of 
150 pre-COVID levels, p<0.05). This recovered to 47 per week in W2 (118% of pre-COVID 
151 levels).
152
153 Figure 2B shows that, of the 20 sites that reported use of exercise stressor pre-COVID-19, 14 
154 sites (70%) had stopped their exercise stress echocardiography (ESE) service either due to 
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155 ceasation of all stress echocardiography (4 sites – 20%) or had replaced it with a dobutamine 
156 stress only service (10 sites – 50%) during W1. The 6 sites (30%) continuing their exercise 
157 stress service during W1 reported reduced patient numbers and a requirement to wear Level 2 
158 PPE (fluid repllent disposable gown, respirator mask, gloves, eye protection). 
159 Of the 16 sites who responded during W2 and performed exercise stress pre-COVID-19, 3 
160 sites (19%) had stopped their ESE service during W2. Of the 13 sites still performing ESE 




165 Impact on Patients and Personal Protective Equipment
166 Figure 4A illustrates the screening procedures used at the sites across the two waves. 60% of 
167 sites performed temperature checks during W1 and 63% did so during W2. During W1, 2 sites 
168 performed COVID-19 swab tests between 2 and 3 days prior to the appointment, with 1 site 
169 performing swab test after the stress echo. The two sites performing swabs in W2 did so 72 
170 hours and 4-7 days pre-appointment, respectively. 20% of sites asked patients to self-isolate 
171 during W1, with 2 sites requiring 7 days and two 14 days. During W2, 2 sites (11%) required 
172 patients to self-isolate for 3 days (at one site) or 4 days (at the other) after their swab test, 
173 prior to their appointment.   
174 Figures 4B, C and D provide more detail on the use of screening questionnaires at sites. 18 
175 sites (90%) asked patients to complete a health questionnaire during W1, while 13 (68%) sites 
176 used questionnaires during W2. 7 different questionnaires were used by sites during W1, with 
177 most sites using either trust-derived (6 sites – 33%) and BSE (6 sites – 33%) questionnaires. 
178 6 different questionnaires were used during W2, with the majority of sites using trust-derived 
179 questionnaires (8 sites – 62%). The questionnaires were administered pre-appointment (41% 
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180 in W1, 23% in W2), at the appointment (47% in W1, 54% in W2) and both pre-appointment 
181 and on the day (12% in W1, 23% in W2). 25% of patients had not proceeded to stress echo 
182 based on the questionnaire at 1 site during the first wave. No sites reported this incidence rate 
183 during the second wave. 10% of patients did not proceed at 22% of sites in W1 and 31% of 
184 sites during W2. The remainder reported the questionnaire had not identified any patients. No 
185 cases of patients passing the questionnaire with a positive swab test were reported across both 
186 waves at all sites.
187
188 All sites, with the exception of one site during W2, performing stress echocardiography 
189 reported every patient is required to wear a face mask/covering for the procedure (Figure 
190 5A).  For dobutamine stress echocardiography, surgical masks were worn by staff in 90% of 
191 sites during W1 and 84% during W2. 50% and 62% of sites reported use of surgical masks for 
192 exercise echocardiography during W1 and W2, respectively. The other sites required 
193 FFP3/N95 masks. 
194
195 Staff and ongoing impact
196 During W1, 42% of sites were reviewing their stress echo practice weekly, falling to 5% of 
197 sites reviewing practice weekly during W2 (Figure 6A). During W1, the majority of sites 
198 (54.2%) reported that none of their staff were unable to perform stress echocardiography due 
199 to COVID-19. This number fell to 37% during W2, with 11% of sites reporting 25-50% of 
200 their staff were affected (compared to 0% during W1) (Figure 7A). The effects of COVID-19 
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205 Discussion
206 This study shows stress echocardiography practice had restarted within a few months of the 
207 peak infection rate in the majority of hospitals during the first wave of COVID-19 hospital 
208 admissions, albeit at a reduced rate. During the second wave of COVID-19, stress 
209 echocardiography practice has been able to operate at a level not significantly different from 
210 pre-COVID-19 rates. The impact of the first wave and subsequent recovery in W2 was not 
211 different between high and low volume centres.
212
213 The reduction in capacity during W1 is likely to have generated a significant backlog of 
214 patients and, although our findings suggest a return to similar levels of activity in W2, this 
215 will not have been sufficient to clear this backlog. The reduction in capacity during W1 may 
216 have been mitigated by use of clinical triage to identify potentially inappropriate requests or 
217 suggest transfer to alternative imaging tests. However the return to normal activity in W2 
218 would suggest any rationing or redistribution of care was only required for a short period. 
219 This is supported by our observation using data from the EVAREST study that rates of 
220 positive stress studies were very similar during November 2020 to January 2021 (14%) as 
221 before the onset of the COVID pandemic (18%). 
222
223 The major change in practice during W1 was a shift from exercise to dobutamine being used 
224 as the stressor. By W2  most exercise stress services have restarted. The number of patients 
225 seen per session was reduced during both waves, likely to allow for aerosol dispersion and 
226 cleaning. The slight increase in number of stress echo clinics per week during the second 
227 wave likely reflects a compensation to maintain patient numbers when there is an average 
228 reduction in number of patients per list. However, a significant heterogeneity in use of PPE 
229 and patient preparation prior to stress echocardiography is evident in both waves.
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230
231 The major variation between sites was the selection of screening tests for risk of COVID-19 
232 in individual patients. Current BSE guidance recommends varying degrees of screening, from 
233 a COVID symptom questionnaire for DSE and TOE patients, up to asking patinets to self-
234 isolate for two weeks followed by a negative swab test 72/48 hours before their exercise 
235 stress echo. The guidance suggests that the intensity of screening should be adjusted 
236 according to the current local prevalence of COVID positive cases12.
237
238 Variation also exists in the use of PPE with only 38% of sites still performing exercise stress 
239 during W2 using Level 2 personal protective equipment. Departmental policies on use of PPE 
240 did not appear to have any significant association with staff absence rate. There is a paucity 
241 of data with regard to the aerosol generating potential of exercise stress echocardiography. 
242 British Society of Echocardiography guidance states that the consensus opinion amongst 
243 stress echo experts in the UK is that exercise stress echocardiography may be considered an 
244 aerosol generating procedure12. There is, therefore, a need for more investigation into 
245 whether exercise stress echocardiography has an increased risk of infection and, until 
246 evidence to the contrary, current BSE guidance has remained unchanged. It is possible, the 
247 wider use of faster testing and even vaccination passports, as the vaccination programme 
248 continues to expand, could be integrated into stress echocardiography practice to reduce 
249 transmission.
250
251 It is important to note that the results for W1 presented in this paper were collected in July, 
252 several weeks after the first peak of the COVID-19 pandemic in the UK, when stress 
253 echocardiography practice may have been more adversely affected by staff redeployment and 
254 infection rates. Additionally, the numbers of studies performed per month during the two 
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255 waves are estimated, based on the reported number of sessions per week. Hard data on the 
256 number of studies would provide a more robust evaluation of the effect of the pandemic on 
257 the number of studies performed.
258
259 In summary, while the number of studies performed did fall during the first wave of 
260 infections, there has been no long lasting impact on ability to deliver stress echocardiography 
261 within the NHS during the COVID-19 pandemic. During the second wave most services were 
262 oprating at normal rates and services had fully adapted to take account of requirements to 
263 reduce risk of exposure through use of alternative stressors and PPE. Significant 
264 heterogeneity in screening tests and personal protective equipment used may require 
265 standardised national guidance to ensure consistency but local flexibility of service design 
266 may explain the apparent resilience of the cardiology centres to deliver stress 
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271 Figure 1: A – Location of the 26 NHS hospital sites surveyed. B – Range of IMD ranks for 
272 each hospital, demonstrating the wide range of socio-economic backgrounds represented. 
273 (The lower the ranking, the greater the level of socio-economic deprivation). C – Hospital 
274 size as measured by number of beds. D – Hospital cardiology department size, as measured 
275 by number of cardiology attendances per year. E – Volume of stress echocardiograms 
276 performed at each hospital per year. Two of the 24 hospitals who responded to the survey 
277 (Broomfield Hospital and Basildon Hospital) are grouped under the same trust name, 


















Page 12 of 30Accepted Manuscript published as ERP-20-0043.R1. Accepted for publication: 11-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/20/2021 03:31:19PM
via free access
296 Figure 2: A – Reported general stress echocardiography service at sites during the first wave 
297 (n=24) and second wave (n=19). B – Reported exercise stress exchocardiography service. 
298 Percentage reported as proportion of sites who performed ESE before COVID-19 (n=20 W1, 
299 n=16 W2). C – The number of stress echocardiography sessions performed at the sites pre-
300 COVID (n=25), during the first wave (n=20) and second wave (n=18 – one site did not 
301 report). The number of sessions per week, pre-COVID, has been estimated using the reported 
302 annual number of studies, assuming 4 patients per session. D - The reported number of 
303 patients seen in each stress echocardiography session, as reported in a sub-set of sites (n=7) E 
304 - The number of sites performing dobutamine and exercise stress echocardiography before 
















Page 13 of 30 Accepted Manuscript published as ERP-20-0043.R1. Accepted for publication: 11-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/20/2021 03:31:19PM
via free access
321 Figure 3: A - The estimated number of stress echocardiography studies performed at each 
322 hospital site pre-COVID-19 (n=16), during the first (n=16) and second (n=16) waves. Pre-
323 COVID-19 numbers are self-reported data previously collected as a part of the EVAREST 
324 study. Current COVID-19 numbers are an estimation based on the reported number of stress 
325 echocardiography sessions being performed weekly at each site, assuming 4 patients per 
326 session pre-COVID and 3 patients per session in W1 and W2, as reported in Figure 2C. N 
327 number reduced as only sites who responded to both surveys (W1 and W2) and indicated 
328 number of sessions per week can be compared. B - The estimated number of stress 
329 echocardiography studies performed at high volume centres (>800 stress echo studies per 
330 annum, n=8) pre-COVID, during W1 and during W2. C - The estimated number of stress 
331 echocardiography studies performed at lower volume centres (<=800 stress echo studies per 
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346 Figure 4: A – The COVID-19 screening tests currently performed by the NHS sites 
347 performing stress echo during the first wave (n=20) and second wave (n=19). B – Pie chart 
348 illustrating the different questionnaires used by the NHS sites during the first wave (i – n=18) 
349 and second wave (ii – n=13). C – The point in the patient pathway during which the 
350 questionnaire is administered at sites during the first wave (n=18) and second wave (n=13). D 
351 – Percentages of patients failing the COVID-19 screening questionnaire during the first wave 
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370 Figure 5: A – The PPE required for patients to wear during stress echo at sites during the 
371 first wave (n=20) and second wave (n=19). B – The percentage of sites requiring staff to 
372 wear each item of personal protective equipment during dobutamine stress echo in the first 
373 wave (n=20) and second wave (n=19). C – The percentage of the sites performing exercise 
374 stress echocardiography requiring staff to wear each item of personal protective equipment 
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394 Figure 6: A –The frequency with which the NHS sites reviewed the changes made to stress 
395 echocardiography practice at their site during the first wave (n=24) and second wave (n=19). 
396 B – Duration of which the NHS sites anticipated the special measures put in place at their 
397 site, due to the COVID-19 pandemic, to continue for as collected during the first wave (n=24) 
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420 Figure 7: A –The number of staff whom were unable to perform stress echocardiography at 
421 the NHS sites due to COVID-19 during the first wave (n=24) and second wave (n=19). B – 
422 The number of staff whom were unable to perform resting echocardiography at theNHS sites 
423 due to COVID-19 during the first wave (n=24) and second wave (n=19). C – The association 
424 between the level of PPE used and staff absence rates for the sites performing dobutamine 
425 and exercise stress echocardiography during the first wave. D - The association between the 
426 level of PPE used and staff absence rates for the sites performing dobutamine and exercise 
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Appendices
Appendix 1 - Impact of COVID-19 on UK Stress Echocardiography Services’ Survey
Performance of Stress Echocardiography
Is stress echocardiography currently being performed in your hospital?
- Yes, stress echocardiography service unaffected
- Yes, but reduced patient numbers
- Yes, but limited to dobutamine stress echocardiography only
- Yes, but reduced patient numbers AND dobutamine stress echocardiography only
- No
If you are currently performing stress echocardiography, how many sessions do you 
perform each week?
If no, how are patients who have been/would have been referred for stress 
echocardiography now being managed? *
- Referral for alternative test: MPS
- Referral for alternative test: CTCA
- Referral for alternative test: ETT
- Referral for alternative test: Other (Please specify)
- On stress echocardiography waiting list for when clinics resume
- Other (Please specify)
If other, please specify the alternative management approach
Has COVID-19 impacted on your EXERCISE stress echocardiography service? 
- Yes, stopped until further notice and now only performing dobutamine stress 
echocardiography
- Yes, continuing with PPE for staff
- Yes, continuing with reduced patient numbers
- Yes, continuing with PPE for staff and reduced patient numbers
- No, continuing unaffected
- N/A (Exercise stress echocardiography not performed at our hospital)




If yes, for how long do you ask them to self-isolate before their stress echocardiogram?
Pre-Screening
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If yes, which questionnaire do you use?
If yes, when is this questionnaire performed? *
If yes, approximately what percentage of patients fail the questionnaire?




Do you perform COVID-19 swab testing prior to the stress echo?
- Yes
- No
If yes, how long before the stress echocardiogram is this performed?
If yes, where is this performed? 
If yes, if the patient has completed a screening questionnaire, approximately what 
percentage had a negative questionnaire then had a positive swab result? 
PPE
What level of PPE do staff wear when performing EXERCISE stress echocardiography? 





- FFP3/N95 mask (or equivalent)
- Face visor/eye protection
- Other (Please specify)
- N/A (Exercise stress echocardiography not performed at our hospital)
If other, please specify
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What level of PPE do staff wear when performing DOBUTAMINE stress 





- FFP3/N95 mask (or equivalent)
- Face visor/eye protection
- Other (Please specify)
- N/A (Dobutamine stress echocardiography not performed at our hospital)
If other, please specify
Are patients required to wear a face mask or face covering?
- Face mask (Surgical/FFP3/N95 etc.)
- Face covering (Cloth/Homemade etc.)
- Not required to wear
If yes, which procedures are patients required to wear face coverings/masks for?
- Exercise Stress Echocardiography
- Dobutamine Stress Echocardiography
- Both Exercise and Dobutamine Stress Echocardiography
Review of COVID-19 Procedures
If there has been an impact on how stress echocardiography is performed in your hospital, 








How long do you anticipate the COVID-19 special measures to continue for? 
- 1 - 3 Months




Have you had staff unable to perform STRESS ECHOCARDIOGRAPHY during the last 
three months because they have been shielding, in self isolation or diagnosed with COVID-
19 disease? 
- No
- Yes, <10% of staff affected
- Yes, 10-25% of staff affected
- Yes, 25-50% of staff affected
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- Yes, >50% of staff affected
- Unknown
Have you had staff unable to perform RESTING ECHOCARDIOGRAPHY (TTE/TOE) 
during the last three months because they have been shielding, in self isolation or diagnosed 
with COVID-19 disease? 
- No
- Yes, <10% of staff affected
- Yes, 10-25% of staff affected
- Yes, 25-50% of staff affected
- Yes, >50% of staff affected
- Unknown
Do you know what the incidence of COVID-19 disease is amongst all staff at your 
hospital?
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